Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N. Sato J, et al. Among authors: koyama t. Clin Cancer Res. 2022 May 2;28(9):1783-1791. doi: 10.1158/1078-0432.CCR-21-3518. Clin Cancer Res. 2022. PMID: 35180771 Free PMC article. Clinical Trial.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Sunami K, et al. Among authors: koyama t. Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2. Cancer Sci. 2019. PMID: 30742731 Free PMC article.
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N. Ebata T, et al. Among authors: koyama t. Invest New Drugs. 2020 Apr;38(2):468-477. doi: 10.1007/s10637-019-00787-3. Epub 2019 May 24. Invest New Drugs. 2020. PMID: 31124055 Free PMC article. Clinical Trial.
Improved survival among patients enrolled in oncology phase 1 trials in recent decades.
Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N. Ebata T, et al. Among authors: koyama t. Cancer Chemother Pharmacol. 2020 Feb;85(2):449-459. doi: 10.1007/s00280-019-03992-2. Epub 2019 Nov 19. Cancer Chemother Pharmacol. 2020. PMID: 31745590 Clinical Trial.
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M. Doi T, et al. Among authors: koyama t. Oncologist. 2020 Sep;25(9):e1292-e1302. doi: 10.1634/theoncologist.2020-0249. Epub 2020 Apr 23. Oncologist. 2020. PMID: 32324927 Free PMC article. Clinical Trial.
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
Kitano S, Shimizu T, Koyama T, Ebata T, Iwasa S, Kondo S, Shimomura A, Fujiwara Y, Yamamoto N, Paccaly A, Li S, Rietschel P, Sims T. Kitano S, et al. Among authors: koyama t. Cancer Chemother Pharmacol. 2021 Jan;87(1):53-64. doi: 10.1007/s00280-020-04161-6. Epub 2020 Nov 4. Cancer Chemother Pharmacol. 2021. PMID: 33146741 Free PMC article. Clinical Trial.
3,121 results